<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db01225 DrugCentral: enoxaparin Synonymous : None 
Drug Sentece Context Table 1. Analysis of context sentence of enoxaparin gene in 57 abstracts.   pmid  sentence      32294289  Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.">

  
  <link rel="alternate" hreflang="en-us" href="https://bio-hub.github.io/drugpanel/enoxaparin/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://bio-hub.github.io/drugpanel/enoxaparin/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://bio-hub.github.io/drugpanel/enoxaparin/info/">
  <meta property="og:title" content="ENOXAPARIN | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db01225 DrugCentral: enoxaparin Synonymous : None 
Drug Sentece Context Table 1. Analysis of context sentence of enoxaparin gene in 57 abstracts.   pmid  sentence      32294289  Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."><meta property="og:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://bio-hub.github.io/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>ENOXAPARIN | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">ENOXAPARIN</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db01225' target='_blank'>db01225</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=enoxaparin" target="_blank">enoxaparin</a> <br>
Synonymous : <em>None</em>
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>enoxaparin</em> gene in 57 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="/publication/32294289" target="_blank">32294289</a>
</td>
<td style="text-align:center;">
Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32329881" target="_blank">32329881</a>
</td>
<td style="text-align:center;">
Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C 6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32469045" target="_blank">32469045</a>
</td>
<td style="text-align:center;">
Dispensing of hydroxychloroquine, azithromycin, enoxaparin, and sedative medications increased substantially during the pandemic period (P &lt; 0.01 for all comparisons).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32532948" target="_blank">32532948</a>
</td>
<td style="text-align:center;">
A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%. […] After one week the patient significantly improved and the daily dose of enoxaparin was reduced and definitively discontinued four days later.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32560658" target="_blank">32560658</a>
</td>
<td style="text-align:center;">
Standard doses of LMWH (e.g., enoxaparin 4000 IU/24 h SC) are proposed in case of intermediate thrombotic risk (BMI &lt; 30 kg/m<sup>2</sup>, no other risk factors and no ARDS). […] In all obese patients (high thrombotic risk), adjusted prophylaxis with intermediate doses of LMWH (e.g., enoxaparin 4000 IU/12 h SC or 6000 IU/12 h SC if weight &gt; 120 kg), or unfractionated heparin (UFH) if renal insufficiency (200 IU/kg/24 h, IV), is proposed.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32586394" target="_blank">32586394</a>
</td>
<td style="text-align:center;">
Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients with COVID19 not requiring Invasive Mechanical Ventilation [IMV], are: a)more effective in preventing clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first: 1. […] Known hypersensitivity to enoxaparin 7. […] Lack or withdrawal of informed consent INTERVENTION AND COMPARATOR: Control Group (Low-Dose LMWH): patients in this group will be administered Enoxaparin (Inhixa®) at standard prophylactic dose (i.e., 4000 UI subcutaneously once day). […] Intervention Group (High-Dose LMWH): patients in this group will be administered Enoxaparin (Inhixa®) at dose of 70 IU/kg every 12 hours, as reported in the following table. […] This dose is commonly used in Italy when a bridging strategy is required for the management of surgery or invasive procedures in patients taking anti-vitamin K oral anticoagulants Body Weight (kg)Enoxaparin dose every 12 hours (IU)&lt;50200050-69400070-89600090-1108000&gt;11010000 The treatment with Enoxaparin will be initiated soon after randomization (maximum allowed starting time 12h after randomization).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32587886" target="_blank">32587886</a>
</td>
<td style="text-align:center;">
In light of the available literature regarding the pro-thrombotic effects of this novel corona virus, we continued full dose anticoagulation with Enoxaparin after the cardiac catheterization and transitioned to rivaroxaban and we also continued the patient on dual antiplatelet therapy prior to discharge.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32591970" target="_blank">32591970</a>
</td>
<td style="text-align:center;">
Substantial clinical improvement was obtained following a management plan, which included tocilizumab, hydroxychloroquine, prednisolone and enoxaparin sodium.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32615987" target="_blank">32615987</a>
</td>
<td style="text-align:center;">
Enoxaparin 8000 IU twice-daily was also administered subcutaneously.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32616524" target="_blank">32616524</a>
</td>
<td style="text-align:center;">
The other four patients received anticoagulant treatment with enoxaparin and 2 of them died.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32617244" target="_blank">32617244</a>
</td>
<td style="text-align:center;">
He required mechanical ventilation and was started on steroids and therapeutic enoxaparin anticoagulation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32633068" target="_blank">32633068</a>
</td>
<td style="text-align:center;">
All patients were receiving pharmacological thromboprophylaxis with either enoxaparin or fondaparinux.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32650356" target="_blank">32650356</a>
</td>
<td style="text-align:center;">
The patient was admitted to our department and treated with hydroxychloroquine, ritonavir, darunavir, azithromycin and enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32655742" target="_blank">32655742</a>
</td>
<td style="text-align:center;">
Due to an abnormal coagulation profile, the patient was started on enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32658849" target="_blank">32658849</a>
</td>
<td style="text-align:center;">
We suggest starting prophylactic anticoagulant therapy for all patients hospitalized with a symptomatic infection with COVID-19, unless contraindicated, with enoxaparin 40 mg SC daily if creatinine clearance is greater than 30 ml/min.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32685302" target="_blank">32685302</a>
</td>
<td style="text-align:center;">
The patient was started on therapeutic enoxaparin sodium, which led to an improvement in oxygenation, and he was eventually downgraded to the medical floors for further management.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32687485" target="_blank">32687485</a>
</td>
<td style="text-align:center;">
She was started on therapeutic doses of enoxaparin sodium, which was continued through her admission.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32689586" target="_blank">32689586</a>
</td>
<td style="text-align:center;">
Despite treatment with prophylactic enoxaparin (initial D-Dimer 1.14 µg/ml FEU (normal &lt; 0.05 µg/ml FEU), D-Dimer increased to above 20 µg/ml FEU and patient continued to spike high fevers. […] This prompted further investigations and upper and lower extremities DVTs were confirmed and managed with enoxaparin 1 mg/kg twice daily. […] Treatment was changed to enoxaparin and no thrombotic events were encountered to date.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32696014" target="_blank">32696014</a>
</td>
<td style="text-align:center;">
Switch from IV unfractionated heparin to subcutaneous low-molecular-weight heparin enoxaparin in therapeutic doses for patients receiving bedside sustained low-efficiency hemodialysis. […] In the same patients, the switch to anticoagulation with therapeutic doses of the low-molecular-weight heparin enoxaparin allowed undisturbed bedside sustained low-efficiency hemodialysis for at least 12 hours. […] Systemic anticoagulation with subcutaneous enoxaparin provides an effective and safe renal replacement procedure in critically ill patients with coronavirus disease 2019 and hypercoagulability.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732087" target="_blank">32732087</a>
</td>
<td style="text-align:center;">
The patient experienced no recurrences under thromboprophylaxis by enoxaparin 40 mg twice daily.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766568" target="_blank">32766568</a>
</td>
<td style="text-align:center;">
Despite enoxaparin 60 mg once daily, only two measurements of the trough anti-Xa were in the upper end of prophylactic range.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32769623" target="_blank">32769623</a>
</td>
<td style="text-align:center;">
The primary endpoint of this study was the occurrence of pulmonary embolism according to the use of standard thromboprophylaxis (i.e. subcutaneous enoxaparin 4,000 international units once daily) or high regimen thromboprophylaxis (i.e. subcutaneous enoxaparin 4,000 international units bid or therapeutic unfractioned heparin).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32794132" target="_blank">32794132</a>
</td>
<td style="text-align:center;">
We retrospectively evaluated 105 hospitalized patients (61 M, 44 F; mean age 73.7 years) treated with subcutaneous enoxaparin: 80 mg/day in normal weight and mild-to-moderate impair or normal renal function; 40 mg/day in severe chronic renal failure or low bodyweight (&lt; 45 kg); 100 mg/day if bodyweight was higher than 100 kg.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32807241" target="_blank">32807241</a>
</td>
<td style="text-align:center;">
Allergy to sodium enoxaparin or other LMWH, UFH or methylprednisolone 6. […] Lack or withdrawal of informed consent INTERVENTION AND COMPARATOR: • LMWH group: patients in this group will be administered enoxaparin at standard prophylactic dosage. […] • LMWH + steroid group: patients in this group will receive enoxaparin at standard prophylactic dosage and methylprednisolone. […] Enoxaparin will be administered in both LMWH group and LMWH + steroid group at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32840805" target="_blank">32840805</a>
</td>
<td style="text-align:center;">
Ninety-four percent of patients received enoxaparin as standard pharmacological prophylaxis for venous thromboembolism. […] Patients with DVT showed mean age = 75.7 years, mean D-dimer levels = 4.02 ng/ml and all of them received enoxaparin for thromboprophylaxis, except one.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32848743" target="_blank">32848743</a>
</td>
<td style="text-align:center;">
Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40-60 mg twice daily) for 7 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32884879" target="_blank">32884879</a>
</td>
<td style="text-align:center;">
In addition to aspirin and Plavix (clopidogrel), the patient was started on a therapeutic dose of enoxaparin due to elevated D-dimer. […] This case illustrates a combination of factors including hypertension, triple therapy (aspirin, clopidogrel, and enoxaparin), and underlying coagulopathy due to COVID-19, which contributed to the life-threatening intracranial hemorrhage in this patient.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32907635" target="_blank">32907635</a>
</td>
<td style="text-align:center;">
The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation. […] Ability to self-administer prefilled enoxaparin injections after instructions received at the study centre or availability of a person living with the patient to administer enoxaparin. […] Contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity. […] Patients randomized to the intervention group will receive subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32908713" target="_blank">32908713</a>
</td>
<td style="text-align:center;">
The decision was made to commence empiric therapeutic enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32936318" target="_blank">32936318</a>
</td>
<td style="text-align:center;">
The therapeutic options have included IVIG, acetylsalicylic acid, tocilizumab, anakinra, enoxaparin, and methylprednisolone.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32963216" target="_blank">32963216</a>
</td>
<td style="text-align:center;">
He received treatment including antibiotics, hydroxychloroquine, tocilizumab, vasopressors, prone positioning, and anticoagulation with enoxaparin at a prophylactic dose. […] Since the patient was hemodynamically stable, we decided to treat him with conventional anticoagulation under close monitoring for signs of hemodynamic deterioration; thus, the prophylactic dose of enoxaparin was replaced by therapeutic dosing, which was a key component of the patient’s successful outcome.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/32977129" target="_blank">32977129</a>
</td>
<td style="text-align:center;">
On ICU admission, patients with D-dimer &lt; 3000 ng/mL (Group 1) received enoxaparin 4000 UI (6000 UI, if body mass index &gt;35) subcutaneously b.i.d. and patients with D-dimer ≥ 3000 ng/mL (Group 2) received enoxaparin 100 UI/kg every 12 h.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32977137" target="_blank">32977137</a>
</td>
<td style="text-align:center;">
In this randomized, open-label, phase II study, we randomized COVID-19 patients requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard anticoagulant thromboprophylaxis. […] Ten patients were assigned to the therapeutic enoxaparin and ten patients to prophylactic anticoagulation. […] Therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33027192" target="_blank">33027192</a>
</td>
<td style="text-align:center;">
The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients. […] The incidence of pulmonary embolism, deep venous thrombosis, major bleeding (MB), clinically relevant non-MB, acute respiratory distress syndrome, and in-hospital mortality was compared between patients on fondaparinux versus enoxaparin therapy. […] 10.5%; P = 0.97) has been shown between the enoxaparin group versus the fondaparinux group.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33041824" target="_blank">33041824</a>
</td>
<td style="text-align:center;">
This review summarizes the available evidence about the role of heparan sulfate as a key entry mechanism for SARS-CoV-2; the efficacy of heparin and LMW heparin in counteracting its entry into the cell, the recent experimental findings obtained in in vitro studies using the LMW heparin enoxaparin Inhixa®, the role of heparin and LMW heparin in modulating the cytokine storm, and the evidence for the use of LMW heparin in the prevention and treatment of the thromboembolic complications of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33043287" target="_blank">33043287</a>
</td>
<td style="text-align:center;">
Thromboprophylaxis with enoxaparin is recommended by current guidelines, but evidence is still weak. […] The aim of this study was to assess the impact of thromboprophylaxis with enoxaparin on hospital mortality in patients admitted for Coronavirus disease 2019 (COVID-19). […] The effects of enoxaparin on intensive care admission and hospital length-of-stay were evaluated as secondary outcomes. […] Seven hundred and ninety nine (57%) patients who received enoxaparin at least once during the hospitalization were included in the enoxaparin cohort, 604 (43%) patients who did not were included in the control cohort. […] At the adjusted analysis enoxaparin was associated with lower in-hospital mortality (Odds Ratio 0·53, 95% C.I. 0·40-0·70) compared with no enoxaparin treatment. […] Hospital length-of-stay was longer for patients treated with enoxaparin (Incidence Rate Ratios 1·45, 95% C.I. […] Enoxaparin treatment was associated with reduced risk of intensive care admission at the adjusted analysis (Odds Ratio 0·48, 95% C.I. […] This study shows that treatment with enoxaparin during hospital stay is associated with a lower death rate and, while results from randomized clinical trials are still pending, this study supports the use of thromboprophylaxis with enoxaparin in all patients admitted for COVID-19. […] Moreover, when enoxaparin is used on the wards, it reduces the risk of Intensive Care Unit admission.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33046998" target="_blank">33046998</a>
</td>
<td style="text-align:center;">
We prospectively evaluated 80 COVID-19 patients, diagnosed using polymerase chain reaction test, who were admitted to our clinic and administered LMWH; LMWH (enoxaparin) was applied according to the weight, D-dimer levels, and clinical condition of patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33054805" target="_blank">33054805</a>
</td>
<td style="text-align:center;">
The patient’s clinical condition improved significantly with anticoagulation, and he was observed in the hospital for 3 days, after which he was discharged home on the enoxaparin bridge with warfarin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33130333" target="_blank">33130333</a>
</td>
<td style="text-align:center;">
All patients had antithrombotic-prophylaxis upon admission using low molecular weight heparin with Enoxaparin. […] They had been treated with curative Enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33133825" target="_blank">33133825</a>
</td>
<td style="text-align:center;">
With his elevated D-dimer of &gt;7,955 ng/mL (reference: 90-500 ng/mL) in the setting of COVID-19 and hypoxia, he was empirically started on therapeutic anticoagulation with enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33138975" target="_blank">33138975</a>
</td>
<td style="text-align:center;">
The most frequently used medication was subcutaneous Enoxaparin (85.2%). […] The Enoxaparin mean dose per day for the whole sample was 49.5 mg + 15.7 (mean + SD).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33159954" target="_blank">33159954</a>
</td>
<td style="text-align:center;">
He developed SARI, cytokines storm and septicaemia, treated with antibiotics, enoxaparin, hydroxychloroquine, insulin, anti-hypertensives, put on ventilator, subsequently developed septicaemia, multi-organ failure and died.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33185785" target="_blank">33185785</a>
</td>
<td style="text-align:center;">
The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33186512" target="_blank">33186512</a>
</td>
<td style="text-align:center;">
Treatment included immunoglobulin (89%); corticosteroids, antibiotics, and enoxaparin in about 50%; and oseltamivir and antifungal therapy in less than 10%.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33186991" target="_blank">33186991</a>
</td>
<td style="text-align:center;">
We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33201172" target="_blank">33201172</a>
</td>
<td style="text-align:center;">
In some patients, additional treatment with tocilizumab, dexamethasone and enoxaparin was adopted. […] Anticoagulant treatment during hospital admission with enoxaparin at a dose higher than 4000 U once daily was associated with a better prognosis. […] Anticoagulant treatment with enoxaparin might be associated to a clinical benefit in terms of survival in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33213364" target="_blank">33213364</a>
</td>
<td style="text-align:center;">
The patient was managed at home, with corticosteroids, nitazoxanide and a single dose of 40 mg of subcutaneous enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33270751" target="_blank">33270751</a>
</td>
<td style="text-align:center;">
Retinal changes were present in 12% (3/25) of patients: a 35 year-old male demonstrated bilateral nerve fiber layer infarcts and microhemorrhages in the papillomacular bundle, but required mechanical ventilation and developed severe anemia and systemic hypotension, acute kidney injury and neurologic symptoms during the course of the disease (critical illness); a 56 year-old male, who required full enoxaparin anticoagulation due to particularly elevated D-dimer (&gt;5.0 mcg/mL), demonstrated unilateral and isolated flame-shaped hemorrhages; and a 49 year-old hypertensive male showed bilateral and discrete retinal dot and blot microhemorrhages.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33273262" target="_blank">33273262</a>
</td>
<td style="text-align:center;">
All patients had antithrombotic-prophylaxis upon admission using lower molecular weight heparin with Enoxaparin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33274479" target="_blank">33274479</a>
</td>
<td style="text-align:center;">
All patients received clarithromycin, enoxaparin and methylprednisolone or prednisone up to 10 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33295704" target="_blank">33295704</a>
</td>
<td style="text-align:center;">
LDH and CPK resulted highest among deceased patients, while the use of enoxaparin was more frequent in survivors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33301232" target="_blank">33301232</a>
</td>
<td style="text-align:center;">
The treatments have been used before side effects occur, included: antimalarial, anti-viral, antibiotics, tocilizumab, enoxaparin and and so on.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33335817" target="_blank">33335817</a>
</td>
<td style="text-align:center;">
Treatment started with antibiotics, prophylactic enoxaparin (40-mg subcutaneous once daily), methyl prednisone 60 mg BD and multivitamins.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33336766" target="_blank">33336766</a>
</td>
<td style="text-align:center;">
They received full-dose anticoagulation, including Enoxaparin 0.5 mg·kg-1 subcutaneously twice a day, unfractionated Heparin 7500 units subcutaneously three times daily, or low-intensity Heparin infusion.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33354679" target="_blank">33354679</a>
</td>
<td style="text-align:center;">
To determine the impact of anticoagulation on inhospital mortality among coronavirus disease 2019-positive patients with the a priori hypothesis that there would be a lower risk of inhospital mortality with use of preemptive therapeutic over prophylactic dose enoxaparin or heparin. […] Preemptive enoxaparin or heparin at a therapeutic or prophylactic dose.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33381763" target="_blank">33381763</a>
</td>
<td style="text-align:center;">
Although therapeutic and prophylactic anticoagulant interventions have been recommended, empiric use of antifactor medications (heparin/enoxaparin) may result in hemorrhagic complications, including death.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33384403" target="_blank">33384403</a>
</td>
<td style="text-align:center;">
The patient was successfully treated with enoxaparin anticoagulation therapy, and symptoms improved over the following 12 days.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33389568" target="_blank">33389568</a>
</td>
<td style="text-align:center;">
The high observed rate of venous thromboembolism prompted us to increase the prophylactic doses of enoxaparin from 40 mg daily up to 1 mg/kg twice daily in patients admitted to intensive care units (ICU), 0.7 mg/kg twice daily in high-intensity of care wards and 1 mg/kg daily in low-intensity of care wards. […] Patients on high enoxaparin doses were compared to those who received prophylaxis with the standard dosage. […] Of 278 patients with Covid-19, 127 received prophylaxis with high enoxaparin doses and 151 with standard dosage. […] Major bleeding occurred in four of 127 patients (3.1%) on the high enoxaparin dosage. […] In conclusion, in the cohort of patients with Covid-19 treated with high enoxaparin dosages we observed a 60% reduction of mortality and clinical deterioration and a 50% reduction of venous thromboembolism compared to standard dosage prophylaxis. […] However, 3% of patients on high enoxaparin dosages had non-fatal major bleeding.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33481739" target="_blank">33481739</a>
</td>
<td style="text-align:center;">
In the convalescent phase, one day after hospital discharge, and enoxaparin suspension, they went back to hospital because STEMI.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33506312" target="_blank">33506312</a>
</td>
<td style="text-align:center;">
Hydroxychloroquine/azithromycin/enoxaparin were used initially, while amiodarone/enoxaparin were used at a later phase.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33509065" target="_blank">33509065</a>
</td>
<td style="text-align:center;">
The patient was treated with different combinations of antivirals (hydroxychloroquine and remdesivir), cytokine inhibitors (anakinra and tocilizumab), glucocorticoids (hydrocortisone and methylprednisolone), and an anticoagulant (enoxaparin).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33522958" target="_blank">33522958</a>
</td>
<td style="text-align:center;">
Enoxaparin was administered to 68 (37.78 %) patients for thromboembolic prophylaxis, and stratification by the D-dimer concentration and DIC score confirmed lower mortality in patients who received enoxaparin when the D-dimer concentration was &gt; 2 than &lt; 2 mg/L or DIC score was ≥ 5 than &lt; 5.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33545499" target="_blank">33545499</a>
</td>
<td style="text-align:center;">
During the 1st period hydroxychloroquine, lopinavir/ritonavir and therapeutic enoxaparin when thrombosis was confirmed were administered; systemic corticosteroids were given in case of severe pneumonia.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="/publication/33574135" target="_blank">33574135</a>
</td>
<td style="text-align:center;">
More than 99% (n=3600) of treated patients received subcutaneous heparin or enoxaparin. 622 deaths occurred within 30 days of hospital admission, 513 among those who received prophylactic anticoagulation.
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
